Skymed Pharmaceuticals Private Limited
About Skymed Pharmaceuticals Private Limited
Data last updated:
Skymed Pharmaceuticals Private Limited is a private limited company based in New Delhi, Delhi, India. It operates in the wholesale trading and distribution segment of the trading and commerce sector. It was incorporated on 16 February 2016 and has been in existence for over 10 years.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U51109DL2016PTC291224. Its GSTIN is 05AAWCS7648M1ZB (Uttarakhand). The company holds 2 GST registrations, of which 1 is active.
The company has an authorised share capital of ₹1 Lakh and a paid-up capital of ₹1 Lakh. It is led by directors Mani Kant Choudhary and Suman Kumar Ishwer.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at C – 15 Nanhey Park Matiyala Bindapur, New Delhi, Delhi, India – 110059.
As per the financials filed for FY 2024, the company reported a revenue of ₹2.27 Lakh, a decline of 16% compared to the previous year. For the same year it recorded a net loss of ₹5,480 (net margin -2.4%) and EBITDA of ₹20,848 (EBITDA margin 9.2%). Revenue has grown at a compounded annual rate (CAGR) of 16% over three years and 1% over five years.
The current compliance status is marked as compliant by the Registrar of Companies.
Company details
Contact details
Skymed Pharmaceuticals Private Limited's registered office is in New Delhi, Delhi. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Registered AddressC – 15 Nanhey Park Matiyala Bindapur, New Delhi, Delhi, India – 110059
- IndustryTrading, Wholesale, Other Wholesale
To see the full contact details of Skymed Pharmaceuticals Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Skymed Pharmaceuticals is trade. In detail, this covers wholesale trading.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading |
To see the full business activity and turnover split of Skymed Pharmaceuticals Private Limited, buy the company report.
Financials of Skymed Pharmaceuticals Private Limited
FY 2025 filings availableSkymed Pharmaceuticals Private Limited reported revenue of ₹2.27 Lakh (down 16% YoY) for FY 2024.
Compounded Annual Growth Rate (CAGR)
Revenue fell 16% in the latest year, but over five years it has grown at a compounded annual rate (CAGR) of 1%. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹20,848 | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | -₹5,480 | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 9.2% | ||||
| Net Profit Margin | -2.4% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Skymed Pharmaceuticals Private Limited, buy the company report.
Board of directors of Skymed Pharmaceuticals Private Limited
Skymed Pharmaceuticals has 2 directors on record. No former directors are listed.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Mani Kant Choudhary | Director | 16 Feb 2016 | 10 Years 8 Months | Current |
| Suman Kumar Ishwer | Director | 16 Feb 2016 | 10 Years 8 Months | Current |
Peer comparison
Skymed Pharmaceuticals Private Limited is compared with the 4 companies closest to it by revenue in the Pharma industry (Pharmaceuticals), with the same principal business activity (wholesale trading), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Levisto Pharmaceuticals Private Limited | ₹2.29 Lakh (FY 2023) | Panchkula, Haryana, India | ||||
| Oricon Pharmaceuticals Private Limited | ₹2.28 Lakh (FY 2024) | -61.0% | Rohtak, Haryana, India | |||
| Inpure Pharmaceuticals Private Limited | ₹2.27 Lakh (FY 2023) | 2170.0% | Delhi, India | |||
| Skymed Pharmaceuticals Private Limitedthis company | ₹2.27 Lakh (FY 2024) | -₹5,480 | -2.4% | -16.0% | New Delhi, Delhi, India | |
| Advance Poly Pathic Pharmaceuticals Limited | ₹2.24 Lakh (FY 2024) | -65.0% | Patna, Bihar, India |
To see the full peer comparison of Skymed Pharmaceuticals Private Limited, buy the company report.
Auditor
Skymed Pharmaceuticals Private Limited is audited by BAS ASSOCIATES for the financial year 2017.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| BAS ASSOCIATES | FY 2017 | 015871N |
Shareholding
The shareholding of Skymed Pharmaceuticals Private Limited is on record for FY 2017, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2017 |
|---|---|
| Promoters | |
| Domestic institutional investors (DII) | |
| Foreign institutional investors (FII) | |
| Public | |
| Others |
To see the full shareholding pattern of Skymed Pharmaceuticals Private Limited, buy the company report.
Legal cases
No court or tribunal cases involving Skymed Pharmaceuticals Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Skymed Pharmaceuticals Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Skymed Pharmaceuticals has 2 GST registrations: 1 active and 1 cancelled or inactive.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 05AAWCS7648M1ZB | Uttarakhand | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Skymed Pharmaceuticals Private Limited, buy the company report.
Recent activity
Skymed Pharmaceuticals Private Limited has 2 board changes on record since 2016: 2 appointments. The latest: Mani Kant Choudhary was appointed as Director on 16 Feb 2016.
Frequently asked questions
Skymed Pharmaceuticals is an active private limited company based in New Delhi, Delhi, India. The company works in wholesale, within the trading industry. It was incorporated on 16 February 2016 (10+ years old) and is registered under CIN U51109DL2016PTC291224.
Skymed Pharmaceuticals has 2 current directors:
- Mani Kant Choudhary - Director
- Suman Kumar Ishwer - Director
The latest financial statements of Skymed Pharmaceuticals on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from FY 2016 are in the company report.
The GSTIN of Skymed Pharmaceuticals is 05AAWCS7648M1ZB, registered in Uttarakhand. The company has 2 GST registrations in all, of which 1 is active and 1 is cancelled or inactive.
The CIN (Corporate Identification Number) of Skymed Pharmaceuticals is U51109DL2016PTC291224. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Skymed Pharmaceuticals was incorporated on 16 February 2016, making it 10+ years old. It is registered with the Registrar of Companies, Delhi.
The peers of Skymed Pharmaceuticals by revenue are Levisto Pharmaceuticals Private Limited, Oricon Pharmaceuticals Private Limited, Inpure Pharmaceuticals Private Limited, Advance Poly Pathic Pharmaceuticals Limited, all in the Pharma industry (Pharmaceuticals), with the same principal business activity (wholesale trading).
Mani Kant Choudhary was appointed as Director on 16 Feb 2016. Suman Kumar Ishwer was appointed as Director on 16 Feb 2016.
The registered office of Skymed Pharmaceuticals is at C – 15 Nanhey Park Matiyala Bindapur, New Delhi, Delhi, India – 110059.
Skymed Pharmaceuticals operates in the trading industry, in the wholesale segment.
The compliance status of Skymed Pharmaceuticals is compliant as of 15 August 2026. The company is actively filing with the Registrar of Companies.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
